{"success":true,"data":{"pressRelease":{"id":"116576","rtpr_id":"nACSPyYKFa","ticker":"MEDS","exchange":"NASDAQ","all_tickers":["MEDS"],"title":"DataMeds AI Provides Update on Corexa Health's Pharmacy Division","author":"ACCESSWIRE","published_at":"2026-08-12T11:40:00.922Z","article_body":"*\nGLP-1 agonist drugs now available\n*\nIntegration of online store CorexaRx.com (http://www.CorexaRx.com) into Health\nLives Here app now complete\n*\nMedical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now\navailable\n*\nRevenue stabilized above $600,000 for July 2026 amid rebranding as pharmacy\nprepares to expand through the launch of Health Lives Here app with NFL Alumni\nHealth\n\nTAMPA, FL / ACCESS Newswire (https://www.accessnewswire.com/) / August 12,\n2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (\"DataMeds AI,\" \"DataMEDS,\" or the\n\"Company\"), an integrated healthcare company leveraging its Health IT\ninfrastructure and artificial intelligence platform EinsteinRx™ combined\nwith blockchain-enabled smart contracts platform PharmacyChain™ to provide\nintegrated solutions for the compliant delivery of healthcare and monetization\nof health data by market participants, today provided an update on the\nCompany's pharmaceuticals-focused subsidiary Corexa Health's pharmacy division\nCorexa Pharmacy. Corexa Pharmacy recently achieved several qualitative and\nquantitative milestones that position it to be the centerpiece of Company\ngrowth in the 2(nd) half of 2026.\n\nRecent Milestones\n*\nRegistration with TrumpRx to be able to offer patients access to oral GLP-1\nagonist drugs, such as Eli Lilly's Foundayo® and Novo Nordisk's oral Wegovy,\nfor as little as $149 out of pocket costs. Injectable GLP-1 agonist drugs are\nalso now available.\n*\nAvailability of GLP-1 agonist companion medical food Forzet®, manufactured by\nTollo Health, LLC, to complement patients' use of GLP-1 agonist drugs for the\ndietary management of muscle loss associated with weight loss therapies.\n*\nLaunch of online store CorexaRx.com/Store (https://pr.report/p1as).\n*\nIntegration of CorexaRx.com/Store (https://pr.report/p1at) into the Health\nLives Here app (via Apple App Store and Google Play) that was recently\nintroduced at the 2026 Pro Football Hall of Fame Game initially exclusively\nfor former NFL players allowing patients to conduct a telemedicine visit and\nbe prescribed and/or refill a GLP-1 agonist drug as well as Forzet, and\nmonitor health data over time while on therapy. The Health Lives Here app is\nexpected to launch to the public in September 2026, with a staged state by\nstate rollout beginning in North Carolina.\n*\nAvailability of Tollo Health, LLC medical food Galectovid™ and dietary\nsupplement Tollovid® targeting customers with acute and chronic viral\ninfections.\n*\nAvailability of other dietary supplements to allow customers to order their\nsuite of nutraceuticals from Corexa Pharmacy alongside their medications.\n*\nPortfolio expansion to non-GLP-1 agonist pharmaceutical drugs in order to\ndispense drugs to patients prescribed GLP-1 agonist drugs, as well as\nmedications for other conditions.\n*\nJuly 2026 revenue exceeded $600,000, stabilizing Corexa Pharmacy's run rate\nabove $7 million annually as the Company prepares to benefit from the\ninitiation of a former NFL player-led influencer campaign to drive downloads,\nphysician visits, GLP-1 agonist drug prescriptions and sales of companion\nproduct Forzet through the Health Lives Here app, marketed together with NFL\nAlumni Health\n\nDataMEDS interim co-CEO Gerald Commissiong commented, \"We are very pleased\nwith the stabilization of revenue in Corexa Pharmacy, which was recently\nrebranded from its prior name Wellgistics Pharmacy. With that rebrand now\ncomplete and significant infrastructure improvements and new proprietary sales\nchannels on the horizon supported by high profile marketing, we believe that\nwe are poised to start driving significant growth through the pharmacy as a\nresult of our proprietary telemedicine platform becoming more broadly\navailable, initially focusing on GLP-1 users. The Health Lives Here app\nprovides a unique window to monitor patients' health, and we believe that\nphysicians will see tremendous value in using our technology platform and\nnovel products to help improve patient outcomes.\"\n\nAbout DataMeds AI, Inc.\n\nDataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company\nthat focuses on the vertical integration of technology, pharmacy,\npharmaceutical-adjacent and telemedicine business units to deliver a better\nhealthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI\nincorporates the artificial intelligence platform EinsteinRx™ and\nblockchain-enabled smart contracts platform PharmacyChain™ into the Health\nLives Here mobile application, and its Corexa Health subsidiary provides\npharmacy and pharmacy services, including the distribution of products\ndeveloped by Tollo Health, LLC.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements include, without limitation, statements regarding: the Company's\nnon-binding letter of intent to acquire a controlling interest in Tollo\nHealth, LLC, and the anticipated timing, structure, terms and completion of\nthat transaction; the Company's proposed acquisition of the QOLPOM\nintellectual property portfolio and the anticipated development and\nintegration of that technology; the Company's license of, and plans to\nintegrate, healthcare delivery intellectual property from DataVault AI Inc.;\nthe Company's plans to expand into telemedicine and diagnostic laboratory\nservices; the Company's proposed transaction with DataVault AI Inc., Scilex\nHolding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or\nwaiver of closing conditions applicable to any of the foregoing; the receipt\nof stockholder approval and any other required approvals; the Company's\nanticipated business strategy, operating plans and growth opportunities; the\nintegration of telemedicine, pharmacy, laboratory, wearable-device, artificial\nintelligence, blockchain and data-management technologies; the proposed\ndevelopment, commercialization and expansion of EinsteinRx AI, PharmacyChain,\nHealth Lives Here and related platforms; the anticipated growth of the market\nfor Long COVID products and related treatment approaches; the Company's\nability to empower patients to access, manage, control or monetize health\ndata; the anticipated benefits of the Company's technology platforms,\nstrategic relationships and business combinations; the Company's\ncapitalization, outstanding securities, lock-up arrangements, public float and\nregistration statements; the Company's ability to maintain compliance with\nNasdaq listing standards; and the Company's liquidity, capital resources and\nability to fund operations; and other risks described in the Company's filings\nwith the Securities and Exchange Commission.\n\nForward-looking statements speak only as of the date of this press release.\nThe Company undertakes no obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\nDataMeds AI Media Contact\nJames Lambert, Vice President\nRubenstein Public Relations\nPhone: 212.805.3024\nEmail: jlambert@rubensteinpr.com\n\nDataMeds AI Investor Contact\nInvestor Relations: IR@wellgisticshealth.com\n\nSOURCE: DataMeds AI, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-provides-update-on-corexa-healths-pharmacy-division-1206399)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSPyYKFa","title":"DataMeds AI Provides Update on Corexa Health's Pharmacy Division","author":"ACCESSWIRE","ticker":"MEDS","created":"2026-08-12T11:40:00.922Z","tickers":["MEDS"],"exchange":"NASDAQ","article_body":"*\nGLP-1 agonist drugs now available\n*\nIntegration of online store CorexaRx.com (http://www.CorexaRx.com) into Health\nLives Here app now complete\n*\nMedical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now\navailable\n*\nRevenue stabilized above $600,000 for July 2026 amid rebranding as pharmacy\nprepares to expand through the launch of Health Lives Here app with NFL Alumni\nHealth\n\nTAMPA, FL / ACCESS Newswire (https://www.accessnewswire.com/) / August 12,\n2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (\"DataMeds AI,\" \"DataMEDS,\" or the\n\"Company\"), an integrated healthcare company leveraging its Health IT\ninfrastructure and artificial intelligence platform EinsteinRx™ combined\nwith blockchain-enabled smart contracts platform PharmacyChain™ to provide\nintegrated solutions for the compliant delivery of healthcare and monetization\nof health data by market participants, today provided an update on the\nCompany's pharmaceuticals-focused subsidiary Corexa Health's pharmacy division\nCorexa Pharmacy. Corexa Pharmacy recently achieved several qualitative and\nquantitative milestones that position it to be the centerpiece of Company\ngrowth in the 2(nd) half of 2026.\n\nRecent Milestones\n*\nRegistration with TrumpRx to be able to offer patients access to oral GLP-1\nagonist drugs, such as Eli Lilly's Foundayo® and Novo Nordisk's oral Wegovy,\nfor as little as $149 out of pocket costs. Injectable GLP-1 agonist drugs are\nalso now available.\n*\nAvailability of GLP-1 agonist companion medical food Forzet®, manufactured by\nTollo Health, LLC, to complement patients' use of GLP-1 agonist drugs for the\ndietary management of muscle loss associated with weight loss therapies.\n*\nLaunch of online store CorexaRx.com/Store (https://pr.report/p1as).\n*\nIntegration of CorexaRx.com/Store (https://pr.report/p1at) into the Health\nLives Here app (via Apple App Store and Google Play) that was recently\nintroduced at the 2026 Pro Football Hall of Fame Game initially exclusively\nfor former NFL players allowing patients to conduct a telemedicine visit and\nbe prescribed and/or refill a GLP-1 agonist drug as well as Forzet, and\nmonitor health data over time while on therapy. The Health Lives Here app is\nexpected to launch to the public in September 2026, with a staged state by\nstate rollout beginning in North Carolina.\n*\nAvailability of Tollo Health, LLC medical food Galectovid™ and dietary\nsupplement Tollovid® targeting customers with acute and chronic viral\ninfections.\n*\nAvailability of other dietary supplements to allow customers to order their\nsuite of nutraceuticals from Corexa Pharmacy alongside their medications.\n*\nPortfolio expansion to non-GLP-1 agonist pharmaceutical drugs in order to\ndispense drugs to patients prescribed GLP-1 agonist drugs, as well as\nmedications for other conditions.\n*\nJuly 2026 revenue exceeded $600,000, stabilizing Corexa Pharmacy's run rate\nabove $7 million annually as the Company prepares to benefit from the\ninitiation of a former NFL player-led influencer campaign to drive downloads,\nphysician visits, GLP-1 agonist drug prescriptions and sales of companion\nproduct Forzet through the Health Lives Here app, marketed together with NFL\nAlumni Health\n\nDataMEDS interim co-CEO Gerald Commissiong commented, \"We are very pleased\nwith the stabilization of revenue in Corexa Pharmacy, which was recently\nrebranded from its prior name Wellgistics Pharmacy. With that rebrand now\ncomplete and significant infrastructure improvements and new proprietary sales\nchannels on the horizon supported by high profile marketing, we believe that\nwe are poised to start driving significant growth through the pharmacy as a\nresult of our proprietary telemedicine platform becoming more broadly\navailable, initially focusing on GLP-1 users. The Health Lives Here app\nprovides a unique window to monitor patients' health, and we believe that\nphysicians will see tremendous value in using our technology platform and\nnovel products to help improve patient outcomes.\"\n\nAbout DataMeds AI, Inc.\n\nDataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company\nthat focuses on the vertical integration of technology, pharmacy,\npharmaceutical-adjacent and telemedicine business units to deliver a better\nhealthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI\nincorporates the artificial intelligence platform EinsteinRx™ and\nblockchain-enabled smart contracts platform PharmacyChain™ into the Health\nLives Here mobile application, and its Corexa Health subsidiary provides\npharmacy and pharmacy services, including the distribution of products\ndeveloped by Tollo Health, LLC.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements include, without limitation, statements regarding: the Company's\nnon-binding letter of intent to acquire a controlling interest in Tollo\nHealth, LLC, and the anticipated timing, structure, terms and completion of\nthat transaction; the Company's proposed acquisition of the QOLPOM\nintellectual property portfolio and the anticipated development and\nintegration of that technology; the Company's license of, and plans to\nintegrate, healthcare delivery intellectual property from DataVault AI Inc.;\nthe Company's plans to expand into telemedicine and diagnostic laboratory\nservices; the Company's proposed transaction with DataVault AI Inc., Scilex\nHolding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or\nwaiver of closing conditions applicable to any of the foregoing; the receipt\nof stockholder approval and any other required approvals; the Company's\nanticipated business strategy, operating plans and growth opportunities; the\nintegration of telemedicine, pharmacy, laboratory, wearable-device, artificial\nintelligence, blockchain and data-management technologies; the proposed\ndevelopment, commercialization and expansion of EinsteinRx AI, PharmacyChain,\nHealth Lives Here and related platforms; the anticipated growth of the market\nfor Long COVID products and related treatment approaches; the Company's\nability to empower patients to access, manage, control or monetize health\ndata; the anticipated benefits of the Company's technology platforms,\nstrategic relationships and business combinations; the Company's\ncapitalization, outstanding securities, lock-up arrangements, public float and\nregistration statements; the Company's ability to maintain compliance with\nNasdaq listing standards; and the Company's liquidity, capital resources and\nability to fund operations; and other risks described in the Company's filings\nwith the Securities and Exchange Commission.\n\nForward-looking statements speak only as of the date of this press release.\nThe Company undertakes no obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\nDataMeds AI Media Contact\nJames Lambert, Vice President\nRubenstein Public Relations\nPhone: 212.805.3024\nEmail: jlambert@rubensteinpr.com\n\nDataMeds AI Investor Contact\nInvestor Relations: IR@wellgisticshealth.com\n\nSOURCE: DataMeds AI, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-provides-update-on-corexa-healths-pharmacy-division-1206399)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-08-12T11:40:00.990182739Z","server_sent_at_ms":1786534800990},"received_at":"2026-08-12T11:40:01.042Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-provides-update-on-corexa-healths-pharmacy-division-1206399"},"analysis":{"id":"105570","press_release_id":"116576","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["Revenue scale remains small (<$1M monthly) despite bullish commentary","Forward-looking statements contain extensive risk factors including pending acquisitions and Nasdaq compliance"],"eventType":"operations_update","narrative":"DataMeds AI reported that its Corexa Pharmacy division achieved stabilized revenue of over $600,000 in July 2026, implying an annualized run rate above $7 million.\n\nThe company completed the integration of its online store into the Health Lives Here app, which launched for former NFL players and will roll out publicly in September.\n\nNew offerings include access to oral and injectable GLP-1 agonists from Eli Lilly and Novo Nordisk for as little as $149, alongside companion medical foods and dietary supplements.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Operational milestone and revenue stabilization, but material impact is limited for current investors given scale."},"keyFigures":{"customDimensions":{"july_2026_revenue":"$600,000","glp1_out_of_pocket_cost":"$149","annualized_revenue_run_rate":"$7,000,000"}},"quotedText":"We are very pleased with the stabilization of revenue in Corexa Pharmacy, which was recently rebranded from its prior name Wellgistics Pharmacy.","namedEntities":{"people":[{"name":"Gerald Commissiong","role":"interim co-CEO"},{"name":"James Lambert","role":"Vice President (Media Contact)"}],"products":["EinsteinRx","PharmacyChain","Health Lives Here app","CorexaRx.com","Foundayo","Wegovy","Forzet","Galectovid","Tollovid"],"companies":[{"name":"DataMeds AI, Inc.","ticker":"MEDS"},{"name":"Corexa Health","relationship":"subsidiary"},{"name":"Eli Lilly","relationship":"partner/supplier"},{"name":"Novo Nordisk","relationship":"partner/supplier"},{"name":"Tollo Health, LLC","relationship":"partner"},{"name":"NFL Alumni Health","relationship":"partner"},{"name":"TrumpRx","relationship":"partner"},{"name":"Rubenstein Public Relations","relationship":"IR/PR firm"}],"dollarAmounts":[{"amount":"$149","context":"out of pocket costs for oral GLP-1 agonist drugs"},{"amount":"$600,000","context":"July 2026 revenue"},{"amount":"$7 million","context":"annualized revenue run rate"}]},"materialImpact":{"score":3,"reasoning":"Operational update highlighting stabilized monthly revenue run-rate ($600k+ in July, implying >$7M annualized) and the launch of a telehealth platform integrated with GLP-1 access. While positive, the figures are pre-revenue scale relative to typical material events, and much of the release outlines strategic positioning rather than finalized financial performance or binary outcomes."},"tickerRelevance":{"others":[],"primary":"MEDS"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"operational-milestone","sectorWeight":"Health Care","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"DataMeds AI reported that its Corexa Pharmacy division achieved stabilized revenue of over $600,000 in July 2026, implying an annualized run rate above $7 million.\n\nThe company completed the integration of its online store into the Health Lives Here app, which launched for former NFL players and will roll out publicly in September.\n\nNew offerings include access to oral and injectable GLP-1 agonists from Eli Lilly and Novo Nordisk for as little as $149, alongside companion medical foods and dietary supplements.","key_figures":{"customDimensions":{"july_2026_revenue":"$600,000","glp1_out_of_pocket_cost":"$149","annualized_revenue_run_rate":"$7,000,000"}},"named_entities":{"people":[{"name":"Gerald Commissiong","role":"interim co-CEO"},{"name":"James Lambert","role":"Vice President (Media Contact)"}],"products":["EinsteinRx","PharmacyChain","Health Lives Here app","CorexaRx.com","Foundayo","Wegovy","Forzet","Galectovid","Tollovid"],"companies":[{"name":"DataMeds AI, Inc.","ticker":"MEDS"},{"name":"Corexa Health","relationship":"subsidiary"},{"name":"Eli Lilly","relationship":"partner/supplier"},{"name":"Novo Nordisk","relationship":"partner/supplier"},{"name":"Tollo Health, LLC","relationship":"partner"},{"name":"NFL Alumni Health","relationship":"partner"},{"name":"TrumpRx","relationship":"partner"},{"name":"Rubenstein Public Relations","relationship":"IR/PR firm"}],"dollarAmounts":[{"amount":"$149","context":"out of pocket costs for oral GLP-1 agonist drugs"},{"amount":"$600,000","context":"July 2026 revenue"},{"amount":"$7 million","context":"annualized revenue run rate"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-12T13:25:59.130Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"operational-milestone","sectorWeight":"Health Care","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":95232,"modelName":"glm-4.7"}}